{
  "name": "Neurogenetics and Neurometabolics",
  "slug": "neurogenetics-and-neurometabolics",
  "icon": "üß¨",
  "color": "bg-indigo-100 text-indigo-800 border-indigo-200",
  "toc": [
    {
      "level": 1,
      "text": "Neurogenetics",
      "id": "neurogenetics"
    },
    {
      "level": 2,
      "text": "Malformations:",
      "id": "malformations"
    },
    {
      "level": 1,
      "text": "Neurocutaneous Disorders",
      "id": "neurocutaneous-disorders"
    },
    {
      "level": 1,
      "text": "Neuro-Metabolic Disorders",
      "id": "neuro-metabolic-disorders"
    },
    {
      "level": 1,
      "text": "Testing for Metabolic Disorders with Neurologic Presentations",
      "id": "testing-for-metabolic-disorders-with-neurologic-presentation"
    },
    {
      "level": 1,
      "text": "Intoxication-Type Inborn Errors of Metabolism",
      "id": "intoxication-type-inborn-errors-of-metabolism"
    },
    {
      "level": 3,
      "text": "Organelle Disorders",
      "id": "organelle-disorders"
    },
    {
      "level": 1,
      "text": "Energy Failure Disorders",
      "id": "energy-failure-disorders"
    },
    {
      "level": 1,
      "text": "Neurotransmitter Disorders",
      "id": "neurotransmitter-disorders"
    },
    {
      "level": 1,
      "text": "Leukodystrophies / Leukoencephalopathies",
      "id": "leukodystrophies-leukoencephalopathies"
    },
    {
      "level": 2,
      "text": "Workup of Leukodystrophies/Leukoencephalopathies",
      "id": "workup-of-leukodystrophies-leukoencephalopathies"
    },
    {
      "level": 1,
      "text": "Childhood disease of the Basal Ganglia",
      "id": "childhood-disease-of-the-basal-ganglia"
    }
  ],
  "html": "<h1 id=\"neurogenetics\">Neurogenetics</h1><h2 id=\"malformations\">Malformations:</h2><p>Classified, in part, based on point in Gestation when went awry (based on Aicardi 1992)</p><div class=\"table-wrap\"><table><tbody><tr><td><p>Gestation</p><p>(weeks)</p></td><td><p>Process</p></td><td><p>Major Morphological CNS Events</p></td><td><p>Corresponding Disorders</p></td></tr><tr><td><p>3-4</p></td><td><p>Primary Neurulation</p></td><td><p>Neural tube, neural crest &amp; derivatives; closure of rostral &amp; caudal neuropores</p></td><td><p>Anencephaly; encephalocele, myelomeningocele; Chiari malformation</p></td></tr><tr><td><p>4-6</p></td><td><p>Telencephalization</p></td><td><p>Dev of forebrain &amp; face; formation of cerebral vesicles; optic &amp; olfactory placodes; fusion of cerebellar plates</p></td><td><p>Holoprosencephaly; Dandy-Walker; craniosynostosis</p></td></tr><tr><td><p>6-16</p></td><td><p>Neuronal &amp; Glial proliferation</p></td><td><p>Cell proliferation in ventricular and subventricular zones; early differentiation of neuroblasts; apoptosis</p></td><td><p>Microcephaly; megalencephaly</p></td></tr><tr><td><p>12-24</p></td><td><p>Neuronal Migration</p></td><td><p>Formation of gyri, distinct GM &amp; WM; migration of cortical neurons; formation of corpus collosum</p></td><td><p>Pachygyria, PMG, Lissencephaly, Schizencephaly, Heterotopias</p></td></tr><tr><td><p>24 - postnatal</p></td><td><p>Organization</p></td><td><p>Late migration; organization and maturation of cortex; synaptogenesis</p></td><td><p>Minor cortical dysplasias</p></td></tr><tr><td><p>24 ‚Äì 2yrs</p></td><td><p>Myelination</p></td><td></td><td><p>Myelination disorders; destructive disorders</p></td></tr></tbody></table></div><ul><li><strong>Malformations of Brain</strong></li><li><em>Agenesis of Corpus Callosum</em></li><li>¬∑       Multiple causes; range of outcomes: subtle left-right integration problems to severe GDD/ID</li><li>¬∑       <strong>Aicardi Syndrome </strong>includes thin unlayered cortex, polymicrogyria and nodular periventricular heterotopias, may have vertebral or costal anomalies and spasms</li></ul><ul><li><em>Holoprosencephaly</em></li><li>¬∑       Fusion of Frontal lobes or whole neocortex, Classified by completeness of fusion</li><li>¬∑       Prone to seizures, MR, endocrinopathies, facial deformity, other midline anomalies</li></ul><ul><li><em>Optic Nerve Hypoplasia Spectrum (Septo-optic dysplasia</em>)</li><li>¬∑       Small chiasm, hypoplastic hypothalamus, absent septum pellucidum</li><li>¬∑       Multiple causes; Often other dysplasias which cause seizures</li><li>¬∑       May have endocrine, visual problems</li></ul><ul><li><em>Hemimegaloencephaly</em></li><li>¬∑       Overgrowth of one hemisphere; numerous syndromic associations. May be associated with mosaicism. Intractable seizures; may require hemispherectomy.</li></ul><ul><li><em>Lissencephaly</em></li><li> Type 1: Classic ‚Äì pachygyria - agyria<ul><li>Smooth, thick brain, may have band heterotopia of subcortical gray matter</li><li>Autosomal (LIS1): Frontal predominance</li></ul></li><li> X-linked (DCX) forms: Posterior predominant</li><li>Type 2: cobblestone-appearing</li></ul><ul><li><strong>Malformations of Skull</strong></li><li><em>Fontanelles:</em></li><li>Posterior usually closes by 1-2 mo, but okay up to 6 mo</li><li>Anterior usually closes by 9 mo, but okay up to 18 mo<ul><li><em>Craniosynostosis:</em> abnormal head shape b/c premature fusion of fissures. Associated with FGF receptor mutations.</li><li><em>Syndromes:</em><ul><li>Apert: AD; syndactyly + brachycephaly 20 to coronal synostosis. May have Agenesis of CC, other brain anomalies.</li><li>Crouzon: synostosis+ malform facial bones. May have ICP probs.</li><li>Carpenter: poly or syndactyly &amp; multiple synostoses. Also may have hypogonadism, obesity brain</li></ul></li></ul></li></ul><ul><li><strong>Chiari Malformations</strong></li><li> <em>Type I</em>: Herniation of cerebellar tonsils through foramen magnum (&gt;5mm)</li><li>Most asymptomatic</li><li>Headache: pain with cough/sneeze; positional pain</li><li>Syrinx: associated with cape-distribution pain or weakness</li><li>May be associated with hydrocephalus</li><li><em>Type II: ‚Äú</em>Arnold-Chiari‚Äù: I + meningomyelocele + posterior fossa abnormalities: displaced, dysplastic lower medulla (beaked tectum); towering cerebellum; often hydrocephalus</li><li><em>Type III</em>: + Encephalocele</li></ul><ul><li><strong><em>Dandy-Walker </em></strong>&amp; Related Syndromes</li><li><strong>Dandy-Walker:</strong> Cystic dilation of the 4th ventricle-post fossa, hypoplastic cerebellum, displaced torcula. Develop hydrocephalus. (‚ÄúDandy Walker Variant‚Äù is an even more vaguely defined term for hypoplastic cerebellum with atypical features.)</li><li>May be isolated finding or associated w/numerous features (agenesis of CC) &amp; syndromes:<ul><li><strong>Walker-Warburg Syndrome </strong>(a severe progressive brain malformation+ retinal dysplasia + muscle dystrophy syndrome)</li><li><strong>Joubert </strong>(abnormal respirations, oculomotor apraxia), other pontocerebellar hypoplasia syndromes.</li><li>Often developmentally disabled due to associated defects rather than 4th Vent per se. Difficult to prognosticate due to myriad etiologies</li></ul></li></ul><h1 id=\"neurocutaneous-disorders\">Neurocutaneous Disorders</h1><p><strong>Neurofibromatosis 1 (NF-1; von Recklinghausen‚Äôs syndrome) </strong></p><ul><li>Genetics: AD; chromosome 17</li></ul><div class=\"callout-box\"><p><strong>NF-1 Diagnostic Criteria</strong></p>\n<p><strong>Requires &gt; 2 of the following</strong></p>\n<ul><li>Parent with NF1</li><li>Caf√© au lait spots &gt; 6    &nbsp;<ul><li>&gt; 5 mm if pre-pubertal     </li><li>&gt; 15 mm if post-pubertal    </li></ul></li><li>2 NFs or one plexiform NF    </li><li>Freckling in axillary/inguinal area    </li><li>Optic glioma</li><li>2 lisch nodules (pigmented iris hamartomas)</li><li>Bony abnormality (sphenoid dysplasia, kyphoscoliosis)</li></ul></div><p><strong>NF-2: </strong>Associated with (bilateral) acoustic neuromas </p><ul><li>AD, chromosome 22</li></ul><p><strong>Tuberous Sclerosis Complex</strong></p><ul><li>Genetics: AD, TSC1 on 9q (hamartin) &amp; TSC2 on 16p  (tuberin<strong>)</strong></li><li>Diagnosis is usually clinical</li><li>Skin lesions are enhanced by a Wood‚Äôs UV lamp</li><li><strong>Rads Work-up</strong><ul><li><strong>MRI:</strong> cortical tubers, SEGAs, subependymal nodules, cortical dysplasias</li><li><strong>Head CT: </strong>calcified tubers within the cerebrum in the periventricular area. </li><li><strong>ECG: </strong>Evaluate for rhabdomyoma (affects &gt; 50% of patients)</li><li><strong>Renal U/S: </strong>renal hamartomas, masses, or polycystic disease</li><li><strong>Renal CT: </strong>May show angiomyolipomas (causing cystic or fibrous pulmonary changes). </li><li><strong>CXR: </strong>May reveal pulmonary lesions or cardiomegaly 2¬∞ to rhabdomyoma </li></ul></li><li><strong>TX: </strong>symptomatic = infantile spasms (vigabatrin), focal seizures, symptoms for SEGAs/ ‚Üë ICP/ intractable epilepsy</li></ul><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>TSC Diagnostic criteria</strong></p></td><td></td></tr><tr><td><p><strong>Definite TSC</strong>: 2 major features or 1 major feature with 2 minor features</p><p><strong>Probable TSC</strong>: One major feature and one minor feature</p><p><strong>       Possible TSC</strong>: Either 1 major feature or 2 or more minor features</p></td><td></td></tr><tr><td><p><strong>Major Features</strong></p></td><td><p><strong>Minor Features</strong></p></td></tr><tr><td><ul><li>Facial angiofibromas or forehead plaque</li><li>Ungual or periungual fibroma</li><li>Hypomelanotic macules (&gt;3)</li><li>Shagreen patch</li><li>Multiple retinal nodular hamartomas</li><li>Cortical tuber</li><li>Subependymal nodule</li><li>Subependymal giant cell astrocytoma</li><li>Cardiac rhabdomyoma, single or multiple</li><li>Lymphangiomyomatosis</li><li>Renal angiomyolipoma</li></ul></td><td><ul><li>Multiple randomly distributed pits in dental enamel</li><li>Hamartomatous rectal polyps</li><li>Bone cysts</li><li>Cerebral white matter migration lines </li><li>Gingival fibromas</li><li>Non-renal hamartoma</li><li>Retinal achromic patch</li><li>‚ÄúConfetti‚Äù skin lesions</li><li>Multiple renal cysts</li></ul></td></tr></tbody></table></div><p><strong>Sturge-Weber Syndrome</strong> (<strong>Encephalo-Trigeminal&nbsp;Angiomatosis</strong>)</p><ul><li>Genetics: Caused by Somatic Activating<strong>&nbsp;Mutation&nbsp;in GNAQ&nbsp;gene</strong> (sporadic)</li><li><strong>Port&nbsp;-wine&nbsp;stains</strong>&nbsp;(nevus flammeus)&nbsp;</li><li>Usually<strong>&nbsp;</strong>seen on Forehead and Upper Eyelid of one side of face; present since birth.</li><li>Light Pink to Deep Purple</li><li>Caused by Overabundance of capillaries&nbsp;around V1</li><li><strong>Associated with&nbsp;</strong></li><li>Secondary Glaucoma (in 50% patients)&nbsp;</li><li>Buphthalmos&nbsp;(enlarged eyeball due to increased intraocular tension)</li><li>Leukocoria (white pupillary reflex)</li><li>Neurologic&nbsp;manifestations: seizures (&gt;75 %, often in infancy), ID, hemiparesis, visual field defects, calcification of tissue and loss of nerve cells in cerebral cortex.</li><li>Ipsilateral&nbsp;Leptomeningeal&nbsp;Angioma&nbsp;(on same side of birth mark; calcification of underlying brain and atrophy of affected region)</li><li>Malformed blood vessels in the&nbsp;piamater&nbsp;overlying the brain on same side of head as the birthmark.</li><li><strong>Radiological</strong>&nbsp;appearance shows&nbsp;Tram-Track&nbsp;Appearance&nbsp;on&nbsp;CT, bilaterally</li><li><strong>Treatment&nbsp;</strong>strategies include&nbsp;Laser surgery,&nbsp;Hemispherectomy</li></ul><p><strong>Inconentia Pigmenti</strong>: Red rash in infancy progresses to patchy hyperpigmentation. Szs starting on DOL 2-3. Genetics = IKBKG ‚ÄúNemo‚Äù; XLD.</p><p><strong>Hypomelanosis of Ito:</strong> Area of  ‚Äùwhorled‚Äù pigmentation due to chromosomal mosaicism. Often a/w seizures &amp; ID </p><p><strong>Ataxia Telangiectasia:</strong>  May have chorea or ataxia; immunodeficiency; elevated AFP; (hematopoietic) malignancy </p><p><strong>Gorlin Syndrome:</strong> Desmoplastic medulloblastoma &amp; Basal Cell Carcinomas, PTC Gene </p><h1 id=\"neuro-metabolic-disorders\">Neuro-Metabolic Disorders</h1><p><strong>Introductory Approach to Classic Neuro-Metabolic Disorders: </strong></p><p>IEMs comprise a group of genetic disorders (AR or X-linked) causing clinically significant block in a metabolic pathway result in either accumulation of a substrate behind a block or a deficiency of the product.  May be classified by pathway, presentation, site of problem in neuro-axis, or under the following categories (detailed review below): </p><ul><li>intoxication-type IEMs (e.g., AAs, OAs, urea cycle d/o), organelle disorders (e.g., paroxysmal, lysosomal, CDGs, nucleus/purines), energy failure disorders (mitochondrial, FA oxidation, Gut-1), or NT d/o. </li></ul><p><strong>1) Distinguish large molecule/organelle disorder vs small molecule disorders. </strong></p><ul><li>Small molecule disorders (e.g., AA &amp; OA disorders): Symptoms often result from energy failure or acute toxic metabolic state (esp. during stress / infection) &amp; often present w/ intermittent decompensation (coma, ataxia). </li><li>Large molecule disorders/organelle disorder (e.g., lysosomal disorder): usually due to accumulation of substances that cannot be metabolized. Typically, these have slow, steady decline. </li><li>Caveat/Exception: Glycogen Storage Diseases = family of d/o comprising both small &amp; large molecule disorders. </li></ul><p><strong>2) Are other organ systems involved? </strong></p><ul><li>Hepatomegaly and or splenomegaly are key features of: <ul><li>Gaucher‚Äôs Disease &amp; Classic Niemann-Pick Disease </li></ul></li><li>Bone changes (Dysostosis Multiplex), apparent as ‚Äúcoarsening of features‚Äù are classic component of ‚ÄúHurler Phenotype‚Äù, and to varying extents, the other mucopolysaccharidoses &amp; related disorders (Mucolipidoses). </li></ul><p><strong>3) Do symptoms and/or MRI pattern suggest gray matter (poliodystrophy) or WM disorder (leukodystrophy)?</strong></p><p>‚Ä¢ GM often have seizures, visual impairment, dementia, focal cortical dysfunctions (e.g. apraxias)</p><p>‚Ä¢ WM disorder often have long-tract signs, neuropathy</p><p>‚Ä¢ Blindness can be an early feature in either gray (e.g. NCL) or white (e.g. ALD) </p><p>‚Ä¢ Tay-Sachs disease has mixed gray and white matter involvement.</p><p><strong>4) Among Leukodystrophies</strong> - Useful distinguishing characteristics:</p><p>‚Ä¢ Peripheral neuropathy and elevated CSF protein (polyradiculopathy)? = Seen in MLD, Krabbe and ALD</p><ul><li>Anterior Predominant: Alexander Disease, MLD, &amp; frontal variant ALD</li><li>Posterior Predominant: X-ALD; Krabbe</li><li>Subcortical ‚ÄúU-fiber‚Äù involvement: Canavan (early in disease)</li></ul><p><strong>5) Is there significant macrocephaly or microcephaly?</strong></p><p>‚Ä¢ Large head is a classic feature of Canavan‚Äôs &amp; Alexander‚Äôs as well as Tay-Sachs</p><p>‚Ä¢ Krabbe more likely to have microcephaly. </p><p><strong>6) Metabolic Disorders with Brain Malformations</strong></p><ul><li>Peroxisomal Disorders &amp; Mitochondrial Disorders</li></ul><p><strong>7) Quick Tips for IEM Work-up:</strong></p><p><strong>Hypoglycemia </strong>seen w/ glycolytic, gluconeogenic, GSDs I &amp; III, mito disorders &amp; organic acidemias </p><ul><li>Unlike other causes, FAOs (&amp; PDH) may be hypoketotic so normal anion gap </li><li>w/severe acidosis, consider LDH &amp; ketolysis defects</li><li>w/acidosis but normal lactate: ketolysis, GSD III, OAs </li></ul><p><strong>Hyperlactemia</strong>: Severe in PDH, PC, ETCs, GSD I &amp; III </p><p><strong>Hyperammonemia </strong>severe in UCDs, NAGS, CPS I, OAs, PC, FAOs </p><ul><li>w/acidosis suggests OAs; w/o acidosis suggests UCDs </li></ul><p><strong>IEM Basic Workup:</strong></p><p>‚Ä¢    <strong>Serum: </strong>Arterial lactate, Pyruvate, NH3, Serum AAs, AcylCarnitine Profile, 3HB/Ketones </p><p>‚Ä¢    <strong>Urine</strong>: OAs, purine/pyrimidines, glycosaminoglycans</p><p>(van Karnebeek 2014)</p><div class=\"callout-box\"><p>Screening for Treatable IEMS</p>\n<p>First Tier: Non-Targeted Screening to identify 54 (60%) treatable IEMs</p>\n<p>Blood:</p><ul><li>Ammonia, lactate</li><li>Plasma AAs</li><li>Total homocysteine</li><li>Acycarnitine profile</li><li>Cu, ceruloplasmin</li><li>Urine:</li><li>Organic acids</li><li>Purines &amp; pyrimidines</li><li>Creatine metabolites</li><li>Oligosaccharides</li><li>Glycosaminoglycans</li></ul>\n<p>Second Tier: Targeted testing to identify 35 (40%) treatable IEMs requiring ‚Äòspecific testing‚Äô:</p>\n<p>Based on patient symptomatology</p><p>WebApp: <a href=\"http://www.treatable-id.org\">www.treatable-ID.org</a> </p><ul><li>Whole blood manganese</li><li>Plasma cholesterol</li><li>Plasma 7-deoxy-cholesterol:cholesterol ratio</li><li>Plasma pipecolic acid &amp; urine AASA</li><li>Plasma VLCFAs</li><li>Plasma Vit B12 &amp; folate</li><li>Serum &amp; CSF lactate/pyruvate ratio</li><li>Enzyme activities (leukocytes): arylsulphatase A, biotinidase, glucocerebrosidase, fatty aldehyde dehydrogenase</li><li>Urine deoxypyridonoline</li><li>CSF: AAs</li><li>CSF: neurotransmitters</li><li>CSF: plasma glucose ratio</li><li>CoQ measurement fibroblasts</li><li>Genetic testing (e.g., CA5A, NPC1, NPC2, SC4MOL, SLC###, PDHA1, DLAT1, PDHX, SPRs, TH)</li></ul></div><h1 id=\"testing-for-metabolic-disorders-with-neurologic-presentation\">Testing for Metabolic Disorders with Neurologic Presentations</h1><p><strong>By Metabolic Test</strong></p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Test</strong></p></td><td><p><strong>Category of disorders</strong></p></td></tr><tr><td><p>UOA (N = 22 treatable IEMs)</p></td><td><p>Organic Acidurias, Mitochondrial, Fatty Acid Oxidation, Aminoacidopathies </p></td></tr><tr><td><p>QSAA (N = 13)</p></td><td><p>Mitochondrial, Aminoacidopathies, Urea Cycle </p></td></tr><tr><td><p>Lactate and Pyruvate </p></td><td><p>Organic Acidurias, Mitochondrial </p></td></tr><tr><td><p>Ammonia </p></td><td><p>Organic Acidurias, Urea Cycle </p></td></tr><tr><td><p>CK </p></td><td><p>Mitochondrial, Myopathies, Muscular Dystrophies </p></td></tr><tr><td><p>Plasma total Homocysteine (N = 9)</p></td><td><p>Homocystinuria, Cobalamin C/D/E/F/G deficiency, MTHFR deficiency</p></td></tr><tr><td><p>Uric Acid </p></td><td><p>Mitochondrial, Fatty Acid Oxidation Disorders, Purine D/o </p></td></tr><tr><td><p>Acylcarnitine Profile </p></td><td><p>Organic Acidurias, Fatty Acid Oxidation Disorders </p></td></tr><tr><td><p>VLCFA and Plasmalogens </p></td><td><p>Peroxisomal Disorders </p></td></tr><tr><td><p>Urine Mucopolysaccharides / GAGs (N = 7)</p></td><td><p>Lysosomal Disorders (e.g., Hurler, Hunter, Sanfilippo)</p></td></tr><tr><td><p>Urine Oligosaccharides (N = 2)</p></td><td><p>Lysosomal Disorders (e.g., Pompe, Gaucher, Sandhoff)</p></td></tr><tr><td><p>WBC Enzymes (2<sup>ND</sup> STEP)</p></td><td><p>Lysosomal Disorders </p></td></tr><tr><td><p>Urine Purines/Pyrimidines (N = 2)</p></td><td><p>Purine and Pyramidine Disorders (Lesch-Nyhan) </p></td></tr><tr><td><p>Urine Creatine metabolites (N = 3)</p></td><td><p>Creatine deficiency syndromes (e.g., AGAT, GAMT, SCL6A8)</p></td></tr><tr><td><p>Buffy Coat, PPT &amp; TPP </p></td><td><p>Neuronal Ceroid Lipofuscinosis </p></td></tr><tr><td><p>IEF for CDG </p></td><td><p>Congenital Disorders of Glycosylation </p></td></tr><tr><td><p>Microarray </p></td><td><p>Chromosomal Duplications or Deletions </p></td></tr><tr><td><p><strong>By CSF test</strong></p></td><td><p><strong>Category</strong></p></td></tr><tr><td><p>Neurotransmitter Metabolites</p><p>(5HIAA, HVA, 3-OMD) *</p></td><td><p>Neurotransmitter Synthesis Disorders </p></td></tr><tr><td><p>BH4 and Neopterin *</p></td><td><p>Neurotransmitter Synthesis Disorders</p><p>Aicardi-Goutierres </p></td></tr><tr><td><p>5MTHF*</p></td><td><p>Cerebral Folate Deficiency </p></td></tr><tr><td><p>Pyridoxal-5‚Äô-Phosphate </p></td><td><p>Folinic-Acid Responsive Seizures </p></td></tr><tr><td><p>Amino Acids </p></td><td><p>Nonketotic Hyperglycinemia </p></td></tr><tr><td><p>Lactate </p></td><td><p>Mitochondrial </p></td></tr><tr><td><p>Glucose </p></td><td><p>Glut-1 Transporter Deficiency Syndrome </p></td></tr></tbody></table></div><p>* All These three tests require special tubes for collection that need to be requested from laboratory and collected first before other tubes are collected.</p><p><strong>By Category</strong></p><div class=\"table-wrap\"><table><tbody><tr><td><p>Category</p></td><td><p>Types</p></td><td><p>Labs</p></td></tr><tr><td><p>Urea Cycle Defects</p></td><td><p>Ornithine Transcarbomylase def</p><p>Arginosuccinic academia</p><p>Carbamolyphosphate synthetase defic</p><p>Citrullinemia</p></td><td><p>NH4, UOA, SAA</p></td></tr><tr><td><p>Organic acidurias</p></td><td><p>Proprionic aciduria</p><p>Methymalonic aciduria</p></td><td><p>UOA</p></td></tr><tr><td><p>Biotin metabolism</p></td><td><p>Multiple carboxylase deficiency</p></td><td><p>Biotinidase</p></td></tr><tr><td><p>Other aminoacidopathies</p></td><td><p>MSUD</p><p>PKU</p><p>Homocysteinuria</p><p>Nonketotic hyperglycinemia</p></td><td><p>SAA, UOA</p></td></tr><tr><td><p>Carbohydate metabolism</p></td><td><p>Glycogen storage disorders type I (von Gerke)</p><p>Glycogen Synthetase deficiency</p></td><td><p>Glucose</p></td></tr><tr><td><p>Glucose Transporter</p></td><td><p>GLUT I deficiency</p></td><td></td></tr><tr><td><p>Lysosomal metabolism</p></td><td><p>Mucopolysaccharidosis</p><p>Oligosaccharidosis</p><p>Sphingolipidosis (GM1 gangliosidosis type I), Gauchers</p><p>Mucolipidosis</p><p>Lipid storage</p></td><td><p>GAGs</p><p>Urine Oligosach</p><p>Vacuolated lymphocytes, urine OS &amp; acid phosphatase enzyme studies</p></td></tr><tr><td><p>Fatty-acid oxidation disorders</p></td><td><p>VLCAD</p><p>MCAD</p><p>SCAD</p></td><td><p>Acylcarnitine, VLCFA</p></td></tr><tr><td><p>Peroxisomal metabolism</p></td><td></td><td><p>Plasmalogens, VLCFA, phytanic acid</p></td></tr><tr><td><p>Sterol metabolism</p></td><td><p>Smith Lemli Optiz</p></td><td><p>7-dehydrocholesterol</p></td></tr><tr><td><p>Protein glycosylation</p></td><td><p>Congenital disorders of glycosylation</p></td><td><p>Isoelectric focusing of transferring-sialotransferrins</p></td></tr><tr><td><p>Neurocutaneous</p></td><td><p>Tuberous sclerosis</p><p>Incontinentia Pigmenti</p></td><td></td></tr><tr><td><p>Neurotransmission</p></td><td><p>Pyridoxine dependent</p><p>Pyridoxal phosphate</p><p>Folinic acid responsive</p></td><td><p>UOA, CSF AA, SAA, CSF NT</p></td></tr></tbody></table></div><h1 id=\"intoxication-type-inborn-errors-of-metabolism\">Intoxication-Type Inborn Errors of Metabolism</h1><p><strong>Amino Acidopathies</strong></p><ul><li>Impaired neuro function by toxic intermediates and decreased NT production</li><li>Presentations:<ul><li>Acute Neonatal encephalopathy, seizures, cerebral edema</li><li>Global Developmental Delays and Dementia</li></ul></li><li>Lab markers: metabolic acidosis with ketosis; often elevated lactate, hyperammonemia</li><li>Dysmorphology: may affect development of corpus callosum</li><li>Localization: early grey matter, later white matter myelination</li><li>Common Disorders:<ul><li>Homocystinuria: clotting, lens dislocation, Marfan habitus</li><li>Maple Syrup Urine Disease (MSUD; urine smells like burnt sugar)<ul><li>difficulty metabolizing branched chain AAs (<strong>I</strong>soleucine, <strong>L</strong>eucine, <strong>V</strong>aline = I love Vermont)</li><li>3 presentations (Classic, Intermittent, Intermediate)</li><li>Classic: End of 1<sup>st</sup> wk of life w. feeding difficulties, lethargy, coma, seizures, odor</li></ul></li><li>Phenylketonuria (PKU): increased phenylalanine, musty odor</li><li>Nonketotic hyperglycemia: unremitting seizures with hypotonia and hiccoughs</li></ul></li><li>Treat with diet interventions (removing AA above enzymatic block from diet)</li><li>Testing: serum amino acids and urine organic acids</li></ul><p><strong>Organic Acidopathies</strong></p><ul><li>Accumulation of acids (ketones and lactic acid) in biological fluids from abnormalities any number of intracellular biochemical processes including<ul><li>Vitamin Metabolism</li><li>Lipid Metabolism</li><li>Glycolysis</li><li>TCA cycle</li><li>Oxidative Metabolism</li><li>Glutathione Metabolism</li><li>4-aminobutyric Acid</li></ul></li><li>Presentations: <ul><li>Acute Neonatal encephalopathy, sz, cerebral edema</li><li>Infantile presentation with delays</li><li>Vomiting, neutropenia, thrombocytopenia</li></ul></li><li>Dysmorphology: none</li><li>Localization: grey matter</li><li>Common Disorders:<ul><li>Isovaleric Acidemia: can‚Äôt breakdown isoleucine, smell like sweaty socks</li><li>Proprionic Acidemia</li><li>Methylmalonic Acidemia</li><li>Glutaric Aciduria Type I (can be confused with inflicted trauma)</li></ul></li><li>Labs/Testing: serum amino acids and urine organic acids<ul><li>Associated with metabolic acidosis with ketosis; often elevated lactate; hyperammonemia</li></ul></li><li>Treatment: dietary for some</li></ul><p><strong>Urea Cycle Disorders</strong></p><ul><li>Accumulation of NH4 due to inability to convert (detoxify) NH4 to urea via urea cycle</li><li>Symptoms due to ammonia intoxication:<ul><li>Vomiting and lethargy: &gt;200 micrograms/dL</li><li>Coma: &gt;300 micrograms/dL</li><li>Seizure: &gt;500 micrograms/dL</li></ul></li><li>Presentations: vomiting, lethargy, seizures associated w/ severe hyperammonemia &amp; respiratory alkalosis typically within 24hrs of life</li><li>Protein load may trigger decompensation in pts with partial deficiencies or female heterozygotes for OTC</li><li>Common Disorders:<ul><li>OTC deficiency</li><li>Citrullinemia</li></ul></li><li>Dysmorphology: none</li><li>Testing: NH4, SAA, UOA, enzyme tests in WBC or genetic sequencing</li><li>Treatment: diet</li></ul><h3 id=\"organelle-disorders\"><strong>Organelle Disorders</strong></h3><p><strong>Nucleus: Purine Disorders</strong></p><ul><li>Purine biosynthesis generates AMP and GMP</li><li>Clinical Features:<ul><li>Renal: recurrent UTI, stones, failure</li><li>Neurological: GDD, epilepsy, spasticity, dystonia, ataxia, autism, <strong>self-mutilation</strong>, deafness</li><li>Arthritis, gout</li><li>Small stature</li><li>Muscle cramps and wasting</li><li>Anemia</li><li>Immunodeficiency with recurrent infections</li></ul></li><li>Conditions: <strong>Lesch-Nyhan </strong></li><li>Testing: <ul><li>Serum uric acid &amp; 24-hour urine uric acid</li><li>Urine crystals (urate)</li><li>Urine Purines and Pyrimidines </li></ul></li><li>Treatment: <ul><li>Purine-restricted diet</li><li>Allopurinol </li><li>Fluids</li></ul></li></ul><p><strong>Golgi Complex: Congenital Disorders of Glycosylation</strong></p><ul><li>Post-translation processing defect in Golgi where glucose groups are not added properly to proteins</li><li>Multisystem disorders with major CNS involvement</li><li>Primarily seen in patients if Northern European Ancestry, AR inheritance</li><li>Dysmorphology: present, may have inverted nipples, unusual fat pads, brain malformations (esp cerebellar)</li><li>Presentations:<ul><li>Early Infancy: FTT, developmental delay, hypotonia, multi-system failure</li><li>Late Infancy: neurological deterioration with ataxia, mental retardation, retinitis pigmentosa, hypotonia, weakness</li><li>Childhood: short stature, failure of sexual maturation, skeletal abnormalities, liver dysfunction, polyneuropathy</li></ul></li><li>Testing: Iso-Electric Focusing for Congenital Disorders of Glycosylation</li></ul><ul><li><strong>Lysosomal Disorders</strong></li><li>Cytoplasmic vesicles with hydrolytic enzymes that degrade products of cellular catabolism</li><li>Failure of cellular recycling process ü°™ abnormal storage in lysosomes ü°™ cellular swelling, injury &amp; cell death</li><li>Types of Lysosomal Disorders:<ul><li>Mucopolysaccharidoses: disorders of the breakdown of glycosaminoglycans (long chains of amino sugars with acetyl or sulfur groups attached to a protein skeleton) = viscous extracellular matrix<ul><li>MPS 1 = Hurler</li><li>MPS 2 = Hunter (X-linked)</li><li>MPS 3 = Sanfilippo</li><li>Testing: urine Glycosaminoglycans, WBC/Fibroblast Enzymes</li></ul></li><li>Oligosaccharidoses: d/o of breakdown of complex carbohydrate side chains of gylycoproteins<ul><li>Schindler</li><li>Sialidosis</li><li>Testing: urine oligosaccharides, WBC/Fibroblast Enzymes</li></ul></li><li>Sphingolipidoses: d/o of breakdown of membrane lipids that contain ceramides (sphingosine attached to a long chain fatty acid) attached to a polar residue<ul><li>GM1 Gangliosidosis</li><li>GM2 Gangliosidosis ‚Äì Tay Sachs and Sandhoff</li><li>Niemann-Pick Type I (A &amp; B)</li><li><img alt=\"\" src=\"/images/neurogenetics-and-neurometabolics/img-3.jpg\" class=\"max-w-full rounded-lg my-4 mx-auto block\"></li><li>Galactosialidosis</li><li>MLD</li><li>Gaucher</li><li>Fabry</li><li>Krabbe</li><li>Farber</li><li>Multiple Sulphatase Def</li><li>Testing: WBC/fibroblast Enzyme, Oligosaccharides for some, BM Bx for some</li></ul></li><li>Mucolipidoses: def of several lysosomal enzymes<ul><li>I Cell and pseudo-Hurler Dystrophy</li><li>Testing: WBC/Fibroblast Enzyme Studies</li></ul></li><li>Lipid Storage Diseases: <ul><li>Neuronal ceroid lipofuscinosis</li><li>Niemann Pick C and D</li><li>Testing:  Cholesterol Studies on Fibroblasts for NPC; Buffy Coat, PPT and TPP, gene testing</li></ul></li><li>Glycogen Storage Disease Type II: <ul><li>Pompe‚Äôs</li><li>Testing: urine oligosaccharides, WBC/Fibroblast Enzymes </li></ul></li><li>Lysosomal Transport Defects:<ul><li>Cystinosis</li><li>Sialic Acid Storage</li><li>Testing: <ul><li>Cystine Content of WBC for cystinosis</li><li>Free sialic acid in urine for Sialic Acid Storage</li></ul></li></ul></li></ul></li><li>Involve one or more organs (variable clinic features)</li><li>Neurological Features: mental retardation, regression, +/- spasticity, peripheral neuropathy or myoclonic seizures</li><li>Not triggered by environmental factors (fasting, protein, etc)</li><li>Dysmorphology seen in some conditions including: <ul><li>Coarse features; Cherry Red Spot; Visceromegaly; Abdominal and/or Inguinal Hernias; Skeletal Abnormalities</li></ul></li><li>Treatment: BMT for some conditions</li></ul><ul><li><strong>Peroxisomal Disorders</strong></li><li>Peroxisomes breakdown unusual fats (very long chain fatty acids, pristanic and phytanic acid (phunny fats) and make cholesterol and bile acids</li><li>Disorders include problems making peroxisomes (peroxisomal biogenesis disorders, importing proteins to peroxisome, breaking down fats, or making required fats</li><li>Abnormal fats accumulate in tissues)</li><li>Dysmorphology:<ul><li>Skeletal: short proximal limbs and calcific stippling</li><li>Craniofacial abnormalities</li><li>Brain malformations with white matter abnormalities and cysts</li></ul></li><li>Associated Clinical Features:<ul><li>Ocular: retinopathy, cataracts, blindness</li><li>Neurological: hypotonia, deafness, encephalopathy, seizures</li><li>Hepatic: neonatal hepatitis, hepatomegaly, cholestasis, jaundice, cirrhosis</li></ul></li><li>Disorders:<ul><li>Peroxisomal Biogenesis<ul><li>Neonatal: severe hypotonia, seizures, cataracts, severe neonatal jaundice, cholestasis, dysmorphic and skeletal abnormalities, FTT</li><li>Infancy: retinopathy to blindness, sensorineural deafness, jaundice, hepatomegaly, portal HTN, FTT, Dysmorphic features</li><li>Childhood: FTT, osteoporosis, progressive psychomotor retardation, neurologic symptoms, blindness, deafness, dysmorphic features</li><li>Variants: <ul><li>Zellweger syndrome (severe neonatal presentation, life span months)</li><li>Neonatal Adrenoleukodystrophy (slower progression)</li><li>Infantile Refsum (mild variant, onset in early childhood)</li></ul></li><li>Testing: cholesterol, bile acids in serum or urine, LFTs, VLCFA, plasmalogens in RBCs</li></ul></li><li>Peroxisomal Beta-Oxidation<ul><li>Same clinical presentations, just due to different enzyme defects</li><li>Testing: cholesterol, bile acids in serum or urine, LFTs, VLCFA, plasmalogens in RBCs</li></ul></li><li>X-linked Adrenoleukodystrophy<ul><li>Boys (4-10yo): behavioral disturbances, intellectual regression, adrenal insufficiency, leukodystrophy. Become essentially vegetative within 2-4 years</li><li>Young Men and Adult Female Heterozygotes: adrenomyeloneuropathy, spastic paraparesis, sphincter problems, impotence, mixed demyelinating and axonal neuropathy, adrenal insufficiency</li><li>Addison Disease</li><li>Testing: VLCFA</li></ul></li><li>Refsum Disease<ul><li>Retinitis pigmentosa, polyneuropathy, cerebellar ataxia, deafness, anosmia, ichthyosis, skeletal and cardiac symptoms, normal intelligence</li><li>Testing: increased phytanic acid, increased CSF protein</li></ul></li></ul></li><li>Treatment: BMT for some conditions</li></ul><h1 id=\"energy-failure-disorders\">Energy Failure Disorders</h1><p><strong>Mitochondrial Disorders</strong></p><ul><li>Inheritance: mtDNA (maternal), AD or AR (either parent)</li><li>100s of different disorders</li><li>Multisystem presentations but especially involving high-energy organs<ul><li>Brain: migraines, sz, dementia, ataxia, dystonia, myoclonus, brainstem dysfunction, callosal malformations</li><li>PNS: ophthalmoplegia, hearing loss, retinal abnormalities, peripheral neuropathy, autonomic neuropathy</li><li>GI: motility, absorption</li><li>Cardiac: cardiomyopathy, rhythm abnormalities</li><li>Renal: loss of AA</li><li>Hepatic: Hepatitis, Fatty Infiltration</li><li>Pancreas: Diabetes</li><li>Muscle: Myopathy</li></ul></li><li>Stepwise Regressions triggered by<ul><li>Fever</li><li>Fasting</li><li>Infection/Immunization</li><li>Medications: aminoglycoside antibiotics, valproic acid</li></ul></li><li>Testing:<ul><li>mtDNA point mutations</li><li>mtDNA sequencing</li><li>nDNA sequencing</li><li>Tissue<ul><li>Light microscopy</li><li>EM</li><li>Respiratory Chain testing</li><li>qPCR for mtDNA content</li><li>Blue-Native Page</li></ul></li></ul></li><li>Pearls: <ul><li>Nearly impossible to ‚Äúrule out‚Äù mitochondrial disorders</li><li>Normal lactate does not rule out mitochondrial disorders</li></ul></li><li>Treatment: exercise, ketogenic diet for some, CoQ10 for deficiency, vitamins to support function</li></ul><p><strong>Glut-1 Transporter Deficiency Syndrome</strong></p><ul><li>Brain can only use glucose or ketones </li><li>Brain energy deficiency disorder due to insufficient transport of glucose across the blood-brain barrier via the Glut-1 transporter</li><li>Clinical phenotypes<ul><li>Acquired microcephaly, ataxia, spasticity, intractable epilepsy, GDD, spells</li><li>Ataxic ‚Äúcerebral palsy‚Äù with well-controlled epilepsy</li><li>Paroxysmal exercise-induced dyskinesias </li></ul></li><li>Diagnosis: <ul><li>CSF glucose &lt;40 mg/dL with normal CSF lactate</li><li>CSF: serum glucose of &lt;50% (nl &gt;50%)</li><li>SLC2A1 gene test only ~70% sensitive</li><li>RBC glucose uptake study</li></ul></li><li>Treatment: ketogenic diet and avoid inhibitors of Glut1 transporter</li></ul><p><strong>Fatty Acid Oxidation Disorders</strong></p><ul><li>Fatty acid oxidation produces energy for the cell (NADH for respiratory chain and Acetyl-CoA for TCA cycle) and generates ketone bodies in times of catabolic stress</li><li>Heart, liver and muscle can use free fatty acids for energy, brain can only use ketones</li><li>Carnitine shuttles fatty acids into mitochondria as acylcarnitines</li><li>Variable clinical presentations<ul><li>Early infantile intoxication: severe lactic acidosis, cardiomyopathy, hepatopathy</li><li>Late infantile: hypoketotic hypoglycemic coma with liver failure triggered by fasting, surgery, infection</li><li>Adolescent to Adult: chronic weakness, pain, recurrent rhabdomyolysis acute or chronic cardiomyopathy</li></ul></li><li>Conditions:<ul><li>Carnitine Transporter Deficiency: cardiomyopathy, cardiac failure, muscle weakness, liver disease</li><li>Carnitine palmitoyltransferase I Deficiency: severe liver disease, RTA</li><li>Carnitine palmitoyltransferase II Deficiency: severe cardiomyopathy, arrhythmias, liver disease</li><li>VLCAD: cardiomyopathy, liver disease, hepatomegaly, SIDS, recurrent rhabdo</li><li>MCAD: Reye-syndrome or metabolic crisis after fasting with lethargy, nausea, vomiting, coma, seizures, cardiac arrest</li><li>SCAD: metabolic acidosis, progressive ID, hypotonia, occ myopathy, rare hypoglycemia</li></ul></li><li>Testing:<ul><li>Acylcarnitine Profile</li><li>Serum glucose, LFTs, ammonia, lactate, CK, myoglobin</li><li>Free fatty acids and ketones</li><li>Carnitine</li><li>Urine Organic Acids (dicarboxylic acids or acylglycines elevated in some conditions)</li><li>Enzyme studies in fibroblasts or lymphocytes</li></ul></li><li>Treatment:<ul><li>Avoid fasting (corn starch at bedtime)</li><li>Frequent meals low in fat, rich in carbohydrates</li><li>Carnitine supplementation</li><li>NO IV LIPIDS</li></ul></li></ul><h1 id=\"neurotransmitter-disorders\">Neurotransmitter Disorders</h1><p><strong>Clinical Features of Neurotransmitter Disorders</strong></p><ul><li>Neonatal progressive encephalopathy</li><li>Neonatal or infantile medically-refractory epilepsy</li><li>Infantile myoclonic epilepsy</li><li>Extrapyramidal movement disorder (parkinsonism, dystonia, ataxia)</li><li>Ptosis, miosis, oculogyric crisis</li><li>Abnormal autonomic function: hypersalivation, disturbed intestinal motility, disturbances of temperature regulation</li><li>Treated with carbidopa/levodopa, 5HTP, SSRIs, leucovorin</li></ul><h1 id=\"leukodystrophies-leukoencephalopathies\">Leukodystrophies / Leukoencephalopathies</h1><ul><li><strong>Vanishing White Matter Disease: </strong>AR neurological disease. Mutations in any of the 5 genes encoding subunits of the translation initiation factor EIF-2B (EIF2B1, EIF2B2, EIF2B3, EIF2B4, or EIF2B5). Symptoms include cerebellar ataxia, spasticity, optic atrophy, epilepsy, loss of motor functions, irritability, vomiting, coma. </li><li><strong>Adrenoleukodystrophy (X-linked)</strong>: peroxisomal disorder so elevated VLCFA. Usually presets as behavioral, visual, auditory problems in boys &amp; has posterior ü°™  anterior progression with enhancing front on MRI. ‚ÄòLorenzo‚Äôs oil‚Äô corrects serum VLCFAs but doesn‚Äôt help already symptomatic patients. If caught early, consider BMT, Treat for adrenal insufficiency. In women can cause isolated neuropathy. </li><li><strong>Metachromatic leukodystrophy</strong>. Classic form onset &lt;age 5, p/w progressive weakness, behavioral problems, optic atrophy. </li><li><strong>Pelizaues-Merzbacher</strong>: defect of a proteolipid (PLP1) synthesis usual onset in infancy with abnormal eye movements later abnormal limb movements, possible stridor, optic atrophy, developmental regression, seizures. </li><li><strong>Alexander: </strong>onset neonatal to adult, w/ developmental regression, macrocephaly, seizures, spasticity. Usually sporadic. Caused by GFAP mutation. MRI shows deep frontal white matter and basal ganglia FLAIR &amp; enhancement. ‚ÄúRosenthal Fibers‚Äù on autopsy. </li><li><strong>Canavan</strong>: aspartoacylase deficiency. Congenital to juvenile onset progressive encephalopathy, macrocephaly, seizures. Autosomal recessive w/Ashkenazi predilection. High NAA in urine and on MRS of CSF. Affects subcortical (‚Äúu‚Äù) fibers first. </li><li><strong>Krabbe (aka Globoid Cell leukodystrophy</strong>). Most common form is early onset (&lt;6 months) w/ dev regression, extremely irritable, opisthotonos, neuropathy, optic atrophy. Tx w/ early dx responds to BMT.</li></ul><p><strong>*Note:</strong> Later onset variants exist for virtually all of the above entities </p><ul><li><strong>Mixed Polio-Leukodystrophy </strong></li><li><strong>Tay-Sachs:</strong> GM2 gangliosidosis- autosomal recessive. Carrier state, though not disease, common in Ashkenazi pop, has both grey &amp; WM involvement. Macrocephaly common. Exaggerated startle is classic but not pathognomonic. Same enzyme. defect may instead present in later life as psychosis or ataxia or ALS-like disease. </li><li><strong>Sandhoff</strong>: deficiency of Hexosaminidase A as in Tay-Sachs, as well as hexosaminidase B, due to defect of common subunit </li></ul><p><strong>Poliodystrophies:</strong></p><ul><li><strong>Alpers:</strong> not a single disease, term used to describe the phenotype of poliodystrophy doe to mitochondrial disease, with or without liver disease. When deep brain structure involvement predominates (basal gang, thalamus, brainstem) would be labeled Leigh disease. </li><li><strong>Menkes:</strong> ‚Äúkinky hair disease‚Äù due to copper transport defect. Onset in infancy. Developmental regression, stimulus induced myoclonus. Dx by Low plasma copper &amp; ceruloplasmin. </li><li><strong>NCLs</strong>: ‚ÄùNeuronal Ceroid Lipofuscinosis‚Äù- Family of relatively common disorders of protein accumulation. Mostly autosomal recessive, key features are seizures, blindness (retinal and cortical), dementia. </li><li>Early Infant form: Haltia Santuovori Dz</li><li>Late Infantile: Jansky-Bielchowsky</li><li>Later onset forms (or less exactly, the NCLs as a group) known as Batten or Kufs Disease. </li><li>Phenotypes of adult forms overlaps somewhat w/ Huntington‚Äôs &amp; DRPLA.</li></ul><h2 id=\"workup-of-leukodystrophies-leukoencephalopathies\">Workup of Leukodystrophies/Leukoencephalopathies</h2><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Blood</strong></p></td><td></td><td><p><strong>CSF</strong></p></td><td></td></tr><tr><td><p>Cellular elements</p></td><td><p>Lymphocyte granulation: MLD-MSD,  </p><p>Anemias: Mito d/o</p></td><td><p>  Cellular elements</p></td><td><p>Elevated in AGS</p></td></tr><tr><td><p>VLCFA</p></td><td><p>Elevated in X-ALD</p></td><td><p>  Total protein</p></td><td><p>Elevated in Krabbe, MLD</p></td></tr><tr><td><p>Lysosomal Enzyme activities</p></td><td><p>Arylsulfatase A low in MLD</p><p>Galacto-cerebrosidase low in Krabbe</p><p>Fucosidase low in Fucsidosis</p></td><td><p>  Asialotransferrins</p></td><td><p>Elevated in VWMD</p></td></tr><tr><td><p>Lactate</p></td><td><p>Elevated in LBSL</p></td><td><p>  5-MTHF</p></td><td><p>Low in Folate rec defect</p></td></tr><tr><td><p>Asialotransferrins</p></td><td><p>Elevated in CDG (d/o glycosylation)</p></td><td><p>  Lactate</p></td><td><p>Elevated in LBSL</p></td></tr><tr><td><p>Cholestanol</p></td><td><p>Elevated in CTX</p></td><td><p>  Interferon</p></td><td><p>AGS</p></td></tr><tr><td><p>DNA preparation</p></td><td><p>Frequently useful</p></td><td><p>  Glyine</p></td><td><p>Elevated in GLY</p></td></tr><tr><td><p><strong>Urine</strong></p></td><td></td><td><p><strong>Biopsies</strong></p></td><td></td></tr><tr><td><p>Sulfatides</p></td><td><p>Elevated in MLD</p></td><td><p>  Skin</p></td><td><p> MLD, Krabbe, storage dx</p></td></tr><tr><td><p>NAA (organic acids)</p></td><td><p>Elevated in Canavan Dz</p></td><td></td><td></td></tr><tr><td><p>Organic acids</p></td><td><p>Organic acid disorders</p></td><td></td><td></td></tr><tr><td><p>Free sialic acid</p></td><td><p>Elevated in Sialic acid storage d/o</p></td><td></td><td></td></tr><tr><td><p>AGS: Aicardi-Goutieres Syn; CTX: Cerebrotendinous xanthomatosis; GLY: Glycine LE; PMD: Pelizaeus Merzbacher Dz (&amp; LD = like-Dz); LBSL: LE w/ brainstem &amp; spinal cord involvement &amp; lactate elevation; MSD: Multiple sulfatase deficiency; MLC: megalancephalic LE w/ subcort cysts</p></td><td></td><td></td><td></td></tr></tbody></table></div><h1 id=\"childhood-disease-of-the-basal-ganglia\">Childhood disease of the Basal Ganglia</h1><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Childhood disease of the Basal Ganglia</strong></p></td><td></td></tr><tr><td><p><strong>Acute</strong></p></td><td><p><strong>Chronic</strong></p></td></tr><tr><td><ul><li>Hypoxia   </li><li>Hypoglycemia</li><li>Carbon Monoxide poisoning</li><li>HUS</li><li>Osmotic myelinolysis</li><li>Encephalitis</li></ul></td><td><p>Inborn errors of metabolism</p><p>¬∑       Leigh Disease   </p><p>¬∑       MELAS   </p><p>¬∑       Glutaric acidemia type II     </p><p>¬∑       Methylmalonic acidemia</p><p>¬∑       Maple syrup urine disease</p><p>¬∑       Wilsons disease</p><p>¬∑       Degenerative Diseases</p><p>o   Juvenile Huntington disease</p><p>¬∑       Other diseases</p><p>o   NF1</p><p>o   Sequelae of acute insults</p><p>o   Basal Ganglia calcifications</p><p>¬∑       Dysmyelinating diseases</p><p>o   Canavan Disease</p><p>o   Metachromatic leukodystrophy</p></td></tr></tbody></table></div><ul><li>&nbsp;</li></ul><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Conditions associated with Basal Ganglia Calcifications</strong></p></td><td></td></tr><tr><td><p>Endocrine</p><ul><li>Hypoparathyroidism   </li><li>Pseudohypoparathyroidism</li><li>Hyperparathyroidism        </li><li>Hypothyroidism</li></ul><p>Metabolic</p><ul><li>Leigh disease    </li><li>Mitochondrial cytopathy</li><li>Fahr disease</li></ul><p>Congenital or developmental</p><ul><li>Familial idiopathic symmetric basal ganglia calcification       </li><li>Hastings-James syndrome</li><li>Cockayne syndrome       </li><li>Lipoid proteinosis       </li><li>NF       </li><li>TSC       </li><li>Kearns-Sayre syndrome</li><li>Methemoglobinopathy   </li><li>Trisomy 21</li></ul></td><td><p>Inborn errors of metabolism</p><p>¬∑       Leigh Disease   </p><p>¬∑       MELAS   </p><p>¬∑       Glutaric acidemia type II     </p><p>¬∑       Methylmalonic acidemia</p><p>¬∑       Maple syrup urine disease</p><p>¬∑       Wilsons disease</p><p>Degenerative Diseases</p><p>¬∑       Juvenile Huntington disease</p><p>Other diseases</p><p>¬∑       NF1</p><p>¬∑       Sequelae of acute insults</p><p>¬∑       Basal Ganglia calcifications</p><p>Dysmyelinating diseases</p><p>¬∑       Canavan Disease</p><p>¬∑       Metachromatic leukodystrophy</p></td></tr></tbody></table></div>",
  "imageCount": 4,
  "chunkCount": 11
}